Format

Send to

Choose Destination
See comment in PubMed Commons below
Melanoma Res. 2013 Jun;23(3):196-8. doi: 10.1097/CMR.0b013e3283610586.

Treatment of metastatic uveal melanoma with intravenous fotemustine.

Author information

1
Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale Per La Ricerca Sul Cancro, 16132 Genova, Italy. francesco.spagnolo85@gmail.com

Abstract

The purpose of the present study was to retrospectively evaluate the safety and activity of intravenous fotemustine in patients with metastatic uveal melanoma. We report on a series of 25 consecutive patients diagnosed with metastatic uveal melanoma. Fotemustine was administered intravenously as a first-line treatment to all patients. Thrombocytopenia and leukopenia (any grade) were observed in 60 and 52% of patients, respectively. Only two patients discontinued treatment because of toxicity (G3 thrombocytopenia), whereas all other patients were discontinued for progressive disease. Two partial responses were observed. Nine patients had stable disease (disease control rate=44%). The median survival duration was 13.9 months, and the 1-year survival rate was 60%. Intravenous fotemustine is well tolerated and could improve the outcome of metastatic uveal melanoma patients with or without liver involvement, although a randomized prospective trial is required to confirm these results.

PMID:
23624366
DOI:
10.1097/CMR.0b013e3283610586
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center